JPH11158061A - Infusion solution for central vein administration - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide infusion solution for central vein administration that stably contains reducing sugar, amino acids and vitamins for a long period of time. SOLUTION: This infusion solution comprises (A) a solution containing reducing sugar, (B) a solution containing amino acids and (C) a solution containing lipophilic vitamins. In this case, the solution (A) contains vitamin B1 , the solution (B) contains folic acid and the solution (C) contains vitamin C. In addition, vitamin B2 is formulated to the solution (B) or the solution (C). The solution (A) is adjusted in its pH to 3.5-4.5 and the solutions (B) and (C) are adjusted in their pH to 5.5-7.5, respectively.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to an infusion for central venous administration containing reducing sugars, amino acids and vitamins, and containing all vitamins stably.

[0002]

2. Description of the Related Art In many cases, oral administration is not possible for patients and the like after gastrointestinal surgery. Therefore, nutritional management of such patients is generally performed by high caloric infusion (IVH) from a central vein. I have. IVH promotes the recovery and healing of patients by improving and maintaining the nutritional status of the patients, and since its effect is enormous, it is now widely used in the field of surgical treatment.

[0003] In IVH, carbohydrates and amino acids as nutrient sources and electrolytes are usually administered. As an infusion preparation for IVH, a preparation containing all of them has been developed. In general, a preparation of a type in which glucose and an amino acid which cause a Maillard reaction are separately stored in a two-chamber container is commercially available.

[0004] By the way, when IVH is administered for a relatively long period, a deficiency of trace elements or vitamins not contained in the infusion preparation becomes a problem. Particularly, vitamin B ₁ represents, easily fall into deficiency in order to be consumed in glucose metabolism, whereby severe acidosis induced.
Therefore, when IVH does not end in a short time (about one week), it is essential to use vitamins together. Because of the lack of stability, vitamins are formulated solely in the form of mixed vitamin preparations or multivitamin preparations, and are co-injected into IVH preparations for business purposes. However, the co-injection operation is complicated and there is a risk of bacterial contamination during the operation, so that both efficiency and caution are required for the operation, which places a great burden on personnel.

[0005] For this reason, in order to simplify the co-injection work as described above, attempts have been made to blend vitamins into a two-chamber container type IVH preparation. For example, fat and sugar are contained in one of the two chambers, amino acids and electrolytes are contained in the other chamber, and various vitamins are contained in either of them (Japanese Patent Laid-Open Nos. 6-209979 and 8-98). 709). Although fat used here is an important nutrient source, the administration of fat is not always acceptable to all patients, for example, patients with hyperlipidemia, liver disorders, thrombosis, diabetic ketosis, etc. In addition, the administration of fat is contraindicated. The optimal dose of fat may vary from patient to patient, and it may be desirable to administer fat alone. However, in the above-mentioned preparations, specific vitamins are stabilized by blending fats. Therefore, when fats are removed, certain vitamins (for example, vitamin B ₂ ) cannot be stably retained. It was difficult.

[0006] In addition, in order to stably mix water-soluble vitamins B, attempts have been made to make the pH of an infusion solution acidic or not to mix sulfite ions (Japanese Patent Application Laid-Open No. 8-143559). However, in the infusion, vitamin B ₁ represents has been stably incorporated, not specifically shown for the other vitamins.

In IVH, vitamin B ₁ deficiency is a major problem as described above, but deficiencies in other vitamins are by no means negligible. For example, depending on the disease state, deficiency of vitamin C may cause bleeding in tissues such as mucous membranes, and deficiency of vitamin B ₂ may cause stomatitis, stomatitis, glossitis, and the like. Furthermore, it has been reported complications such anemia Vitamin B ₁₂ deficiency and folate deficiency.

Further, when vitamin D is added to a chemical solution contained in a polyethylene or polypropylene container and stored for a long period of time, the content of vitamin D is significantly reduced.
Therefore, there is a risk that calcium absorption disorder and bone embrittlement due to vitamin D deficiency may occur in patients.

[0009]

Accordingly, an object of the present invention is to provide an infusion for central venous administration which contains vitamins stably for a long period of time.

[0010]

In SUMMARY OF THE INVENTION The above situation, the present inventors have as a result of intense research, vitamin B ₁ represents that which can be stably incorporated into the reducing sugar solution of a specific pH, folate certain pH
Found that it is stable for a long time in amino acid solution of vitamin C, and that vitamin C and vitamin A, vitamin D and vitamin E, which are fat-soluble vitamins, are stable together with the above two solutions apart from the above two solutions. Completed the invention.

That is, the present invention relates to an infusion solution comprising a solution (A) containing a reducing sugar, a solution (B) containing an amino acid and a solution (C) containing a fat-soluble vitamin. a) will contain vitamin B _1, solution (B) is contained folate, and containing solution (C) is a vitamin C, further vitamin B ₂ formulated in solution (B) or a solution (C),
Further, the present invention provides an infusion for central venous administration, wherein the solution (A) has a pH of 3.5 to 4.5 and the solutions (B) and (C) have a pH of 5.5 to 7.5.

[0012]

BEST MODE FOR CARRYING OUT THE INVENTION The infusion for central venous administration of the present invention comprises:
It consists of three solutions, a solution (A) containing a reducing sugar, a solution (B) containing an amino acid, and a solution (C) containing a fat-soluble vitamin, which are mixed and used at the time of use. Examples of the reducing sugar to be blended in the solution (A) include glucose, fructose, maltose and the like, and glucose is particularly preferable in terms of blood sugar management and the like. In addition to these reducing sugars, non-reducing sugars such as xylitol, sorbitol, and glycerin can be added. The reducing sugar can be used alone or in combination of two or more.
It is preferable to mix 20 to 450 g / l, especially 150 to 300 g / l.

The solution (A) is further blended with vitamin B ₁ , and the solution (A) has a pH of 3.
The pH is adjusted to 5 to 4.5, preferably to pH 3.8 to 4.2. The pH can be adjusted by appropriately using various commonly used organic acids, inorganic acids, organic bases, and inorganic bases.

Vitamin B₁Of the solution (A) is half
In the case of a dose for 1 day to 1 day, 1 to 1
It is preferable to mix 2 mg, particularly 1.5 to 8 mg. Bitami
B ₁(Thiamine) includes thiamine hydrochloride, thia nitrate
Use min, prosultiamine, octothiamine, etc.
Can be Vitamin B₁In solution (A) containing
Contains vitamin B₁Sulfuric acid to prevent
Preferably substantially free of salts and bisulfite
No.

The amino acids to be added to the solution (B) include various amino acids, such as essential amino acids and non-essential amino acids, such as L-isoleucine, L-leucine, L-lysine and L-lysine.
-Methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine,
L-arginine, L-aspartic acid, L-cysteine, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and the like. These amino acids are preferably purely crystalline amino acids. These amino acids are usually used in the form of free amino acids, but may not be in the free form, and may be pharmacologically acceptable salts, esters, N-acyl derivatives, salts of two amino acids, and peptides. Can also be used in the form of

The preferred amounts of these amino acids in solution (B) (converted in free form) are as follows.

[0017]

[Table 1]

Solution (B) further contains folic acid,
It is adjusted to 5.5 to 7.5, preferably 6.0 to 7.0. The pH can be adjusted by appropriately using various commonly used organic acids, inorganic acids, organic bases, and inorganic bases. Further, folic acid is preferably added in an amount of 0.1 to 1 mg, particularly 0.1 to 0.7 mg, in the solution for half day to 1 day of the solution (B).

The fat-soluble vitamins to be added to the solution (C) include vitamin A, vitamin D and vitamin E.
And vitamin K may be added as necessary. Vitamin A (retinol) may be in the form of an ester such as palmitate or acetate; vitamin D includes vitamin D ₁ , vitamin D ₂ , vitamin D ₃ (cholecalciferol) and their active forms (Hydroxy derivative); vitamin E (tocopherol) may be in the form of an ester such as acetic ester or succinate; vitamin K (phytonadione) may be menatetrenone;
Derivatives such as menadione may be used.

These fat-soluble vitamins are contained in the solution (C) for half a day to one day, and vitamin A contains 1250 to 5
000 IU, especially 1400-4500 IU; Vitamin D
Is 10 to 1000 IU, especially 50 to 500 IU; vitamin E is 2 to 20 mg, especially 3 to 15 mg;
It is preferable to mix 2 to 10 mg, particularly 0.5 to 5 mg.

It is preferable that these fat-soluble vitamins are solubilized in the solution (C) by a surfactant.
As the surfactant used here, for example, polyoxyethylene sorbitan fatty acid ester (Tween 80,
Commercially available products such as Tween 20), polyoxyethylene hydrogenated castor oil (commercially available products such as HCO60), ethylene glycol / propylene glycol block copolymer (commercially available products such as Pluronic F68), etc., which are usually 10 to 1000 mg / l. Used at a concentration of

Vitamin C is further added to the solution (C) to adjust the pH to 5.5 to 7.5, preferably 6.0 to 7.0. Adjustment of pH can be performed by using various organic acids,
It can be carried out using an inorganic acid, an organic base, or an inorganic base as appropriate. As vitamin C (ascorbic acid), a sodium salt or the like can be used, and 20 to 250 mg, particularly 30 to 1 mg, of a solution for half a day to one day in solution (C) is used.
It is preferable to mix 50 mg.

Vitamin B ₂ is added to the solution (B) or the solution (C). As vitamin B ₂ (riboflavin), phosphate ester, its sodium salt, flavin mononucleotide and the like can be used, and the solution (B)
Alternatively, in the solution for half a day to one day in the solution (C), 1 to 1
0 mg, especially 2 to 7 mg, is preferably blended. Vitamin B
₂ is particularly preferably incorporated in the solution (C).

In the infusion of the present invention, any of the solutions (A) to (C) may further contain other vitamins. For example, the solution (A) may further contain a pantothenic acid derivative. This vitamin is a solution (A)
Although it can be blended with any of (C) to (C), it is preferred to blend it with the solution (A) from the viewpoint of improving stability. As the pantothenic acid derivative, in addition to the free form, it can be used in the form of a calcium salt or panthenol which is a reduced form.
Suitably 30 mg, preferably 5-20 mg.

[0025] The solution (B), it is possible to further contain vitamin B _12. This vitamin is also a solution (A) ~
Although it can be blended with any of (C), it is preferably blended with solution (B) from the viewpoint of improving stability. In particular, it is preferred that vitamin B _{12 be} separate from vitamin C. Vitamin B ₁₂ is, for example, during a half day to one day liquid dose content of the solution (B), 1~30μg, and it is preferably formulated 2～10Myug.

Further, vitamin B ₆ is further added to the solution (A),
The solution (B) may further contain a nicotinic acid derivative, and the solution (C) may further contain biotin. These vitamins can also be blended with any of the solutions (A) to (C), but are preferably blended with each of the above solutions from the viewpoint of simplicity of production and the like. The amount of vitamin B _6, for example in a half day to one day liquid dose content of the solution (A), 1-10 mg, and it is preferably a 1.5～7Mg. Vitamin B
₆ (Pyridoxine) may be in the form of a salt such as pyridoxine hydrochloride.

The amount of the nicotinic acid derivative may be, for example, from 5 to 50 m / day for half a day to 1 day of the solution (B).
g, preferably 10 to 45 mg. As the nicotinic acid derivative, derivatives such as amide, sodium salt, methyl ester and the like can be used in addition to the free form.
Biotin is used, for example, in a solution for half day to one day administration of the solution (C) in an amount of 0.01 to 0.3 mg, preferably 0.01 to 0.3 mg.
It is good to mix 1 mg.

On the other hand, as another preferred example of the infusion of the present invention, vitamin B ₆ , vitamin B ₁₂ , a nicotinic acid derivative,
The pantothenic acid derivative and biotin can all be blended in the solution (A). In this example, manufacturing can be simplified without significantly sacrificing stability. Also in this case, the amounts of the components are the same as described above.

The infusion of the present invention can further contain an electrolyte, and the electrolyte can be used in any of the solution (A), the solution (B) and the solution (C). Such electrolytes are not particularly limited as long as they are used in ordinary electrolyte infusions, and include sodium, potassium, calcium, magnesium, phosphorus, chlorine, zinc, and the like.For example, the following compounds, hydrates, Any anhydride can be used.

As the sodium source, sodium chloride,
Sodium acetate, sodium citrate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium sulfate,
Sodium lactate and the like; and solutions (A) to (C)
It is preferable to mix the liquid so as to have a concentration of 25 to 70 mEq / l after mixing. Potassium sources include potassium chloride,
Potassium acetate, potassium citrate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, potassium sulfate, potassium lactate and the like can be mentioned. As a calcium source,
Examples thereof include calcium chloride, calcium gluconate, calcium pantothenate, calcium lactate, and calcium acetate, and are preferably blended so as to have a concentration of 3 to 15 mEq / l after mixing.

Examples of the magnesium source include magnesium sulfate, magnesium chloride, magnesium acetate and the like. It is preferable to mix the magnesium source so as to have 3 to 10 mEq / l after mixing. As the phosphorus source, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium glycerophosphate and the like can be mentioned, and it is preferable to mix them at 5 to 20 mmol / l after mixing. Examples of the chlorine source include sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and the like, and it is preferable that the chlorine source is blended so as to have a concentration of 25 to 70 mEq / l after mixing. Examples of the zinc source include zinc chloride, zinc sulfate and the like.
It is preferable to mix them so as to be 1.

Of these electrolytes, the calcium salt and the magnesium salt are preferably separated from the phosphorus compound and mixed in different solutions. Other electrolytes are not particularly limited, and may be mixed with any of the solutions (A) to (C).

The solution (B) may contain a sulfite and / or a hydrogen sulfite as a stabilizer.
In that case, it is preferable to mix 50 mg / l or less in the solution (B).

The infusion of the present invention comprises a solution (A) and a solution (B)
And the solution (C) is composed of three liquids, and the container for accommodating the three liquids is not particularly limited. For example, each of the two chambers separated by a partition capable of communicating the solution (A) and the solution (B) is provided in each chamber. And a container in which the solution (C) is accommodated in one of the chambers so as to be able to communicate with the container when used. The container for accommodating the solution (A) and the solution (B) is not particularly limited as long as it is a two-chamber container separated by a communicable partition, and for example, the partition formed by easy peeling welding (JP-A-2-4671;
No. 5138), in which a partition is formed by sandwiching between chambers with clips (Japanese Patent Laid-Open No. 63-309263).
JP-A-63-20550, etc.) and those provided with various openable communication means in the partition (see JP-B-63-20550). Among them, those in which the partition walls are formed by easily peelable welding are particularly preferable because they are suitable for mass production and the communication work is easy.

The material of the container may be any of various gas-permeable plastics conventionally used for medical containers and the like, for example, polyethylene, polypropylene, polyvinyl chloride, cross-linked ethylene / vinyl acetate copolymer. , Ethylene / α-olefin copolymers, blends of these polymers, and laminates of these polymers.

The filling and storage of each component in each chamber can be carried out according to a conventional method. For example, a method of filling each chamber in an inert gas atmosphere, plugging, and sterilizing by heating. Is mentioned. Here, as a method of heat sterilization, known methods such as high-pressure steam sterilization and hot water shower sterilization can be adopted. Further, the heat sterilization may be performed in an atmosphere of an inert gas such as carbon dioxide or nitrogen, if necessary.

On the other hand, the container for storing the solution (C) is preferably made of a material at least whose inner wall does not substantially adsorb vitamin D so that vitamin D is not adsorbed. Such materials include, for example, glass, polyethylene terephthalate, polyethylene naphthalate, polyacrylonitrile, cyclic polyolefin,
Examples include polyamide (eg, nylon), polycarbonate, and polyfluoroethylene (eg, Teflon). The solution (C) is contained in a single-layer container of the above-mentioned material or a multilayer container (usually having a volume of about 5 ml) having the above-mentioned material on the inner wall, and sealed with a rubber stopper or the like (see FIG. 1). In this case, it is preferable that a sealing material such as a rubber stopper is also coated with a substance to which vitamin D is not adsorbed (eg, polyfluoroethylene).

The container containing the solution (C) is connected to one of the two chambers containing the solution (A) and the solution (B) so as to be able to communicate with each other when used. As the means, for example, as shown in FIG. 2, there is a method of holding at one mouth of a two-chamber container via a double-ended needle. This can be subjected to continuous mixing by pressing the container of the solution (C) as shown in FIG.

As another example of a container for accommodating the solution (C), a small chamber is formed in one mouth of a two-chamber container as shown in FIG. A peelable and openable small bag fixed in one chamber of a two-chamber container as shown in FIG. 5 can be exemplified.

Further, the infusion solution of the present invention housed in the above-mentioned container is preferably packaged in a gas-impermeable outer container together with a deoxidizer in order to surely prevent deterioration, oxidation and the like. In particular, particularly when a container having a partition formed by easy-peeling welding is used as the container, it is preferable to pack the container in a state where the partition is folded at the partition so that the partition does not communicate with the external pressure. In addition, an inert gas filling packaging or the like can be performed as necessary.

As the material of the gas-impermeable outer container suitable for packaging, films or sheets of various materials generally used in general can be used. For example, ethylene-vinyl alcohol copolymer, polyvinylidene chloride , Polyacrylonitrile, polyvinyl alcohol, polyamide, polyester, and the like, and films or sheets containing at least one of these. It is more preferable that the outer container has a light-shielding property. For example, it can be implemented by applying an aluminum laminate to the film or sheet.

As the oxygen scavenger, various known oxygen scavengers, for example, those containing an iron compound such as iron hydroxide, iron oxide or iron carbide as an active ingredient can be used.
Commercial products such as (Mitsubishi Gas Chemical Co., Ltd.), "Modulan" (Nippon Kayaku Co., Ltd.) and "Sequel" (Nippon Soda Co., Ltd.) can be used.

When the infusion of the present invention is administered, other combination drugs such as trace elements (iron, manganese,
Copper, iodine, etc.), antibiotics and the like can be arbitrarily added and compounded as long as the compounding change does not occur.

[0044]

The infusion for central venous administration of the present invention contains vitamins stably for a long period of time.

[0045]

EXAMPLES Next, the present invention will be further described with reference to examples, but the present invention is not limited to these examples.

Example 1 Glucose and an electrolyte were dissolved in distilled water for injection, and pH was adjusted with acetic acid.
As No. 4, a sugar electrolyte solution was prepared. In addition, vitamin B ₁
(Thiamine hydrochloride), vitamin B ₆ (pyridoxine hydrochloride), vitamin B ₁₂ (cyanocobalamin), nicotinamide, panthenol, and biotin are dissolved in distilled water for injection, mixed with the above-mentioned sugar electrolyte solution, and sterile filtered. hand,
A solution (A) having the composition shown in Table 2 was prepared. In addition, each crystalline amino acid and electrolyte are dissolved in distilled water for injection, and acetic acid is added.
After adjusting the pH to 6, folic acid was added and sterile filtration was performed to prepare a solution (B) having the composition shown in Table 2. The solution (B) contains
Sodium bisulfite concentration 50mg / l as stabilizer
Was added so that 600 ml of the solution (A) and 300 ml of the solution (B) were filled in each chamber of a two-compartment polyethylene container under nitrogen replacement, sealed, and then subjected to high-pressure steam sterilization according to a conventional method.

Separately, vitamin A (retinol palmitate), vitamin D ₃ (cholecalciferol), vitamin E (tocopherol acetate) and vitamin K (phytonadione) were dissolved in polysorbate 80 (solution (C)) at a concentration of 33 mg. / L) and dissolved in distilled water for injection, and then vitamin B ₂ (sodium riboflavin phosphate) and vitamin C (ascorbic acid)
Was added thereto, and the solution was adjusted to pH 6 with sodium hydroxide. The solution was sterile-filtered to prepare a solution (C) having the composition shown in Table 2. A glass container was filled with 4 ml of the solution (C), sealed with a Teflon-coated rubber stopper, and then subjected to high-pressure steam sterilization according to a conventional method. This is placed on the solution (B) side of the two-chamber container,
It was attached via a double-ended needle in a sterile room (see FIG. 2) to obtain an infusion for central venous administration of the present invention.

Example 2 A solution (A), a solution (B) and a solution (C) having the compositions shown in Table 2 were prepared in the same manner as in Example 1. 600 ml of the solution (A) and 300 ml of the solution (B) were filled in each chamber of a polyethylene two-compartment container under nitrogen replacement, and a polyethylene port provided with a polyethylene terephthalate small chamber on the solution (A) side. The members were welded and sealed. Next, 4 ml of the solution (C) was filled in the small chamber of the mouth member, sealed with a Teflon-coated rubber stopper, and then subjected to high-pressure steam sterilization according to a conventional method to obtain an infusion for central venous administration of the present invention.

[0049]

[Table 2]

Comparative Examples 1-2 In the same manner as in Example 1, solutions (A), (B) and (C) having the same composition as in Example 1 shown in Table 2 were prepared. 600 ml of the solution (A) and a solution obtained by adding 4 ml of the solution (C) to 300 ml of the solution (B) were filled in each room of a two-room container made of polyethylene under nitrogen replacement, and sealed, followed by a conventional method. Was subjected to high-pressure steam sterilization according to
Further, a solution obtained by adding 4 ml of the solution (C) to 600 ml of the solution (A) and 300 ml of the solution (B) were filled in each room of a two-room polyethylene container under nitrogen replacement, and then sealed. According to a standard method, high-pressure steam sterilization was performed to obtain Comparative Example 2.

Test Example 1 With respect to the infusion solutions obtained in Examples 1 and 2 and Comparative Examples 1 and 2, the content of each vitamin after sterilization and after further standing at 40 ° C. for 4 months was determined according to the biopharmaceutical method according to the Japanese Pharmacopoeia. It was measured by assay (vitamin B _12, and biotin) or HPLC (other vitamins). Table 3 shows the results of the vitamins whose content was reduced. Table 3 shows the ratio to the blending amount in percentage.

[0052]

[Table 3]

From the results shown in Table 3, the infusion of the present invention shows that
The content of each type of vitamin was within the allowable range even after being left for 4 months. On the other hand, in Comparative Example 1, since vitamin B ₂ and vitamin C were blended in the solution (A), the content of the solution was remarkably reduced. Further, in Comparative Example 2, since vitamin K and vitamin C were blended in the solution (B), the content was reduced to an allowable range or more. Furthermore,
In Comparative Examples 1 and 2, vitamin D was drastically reduced by adsorption to the container.

Examples 3-4 and Comparative Example 3 In the same manner as in Example 1, the solution (A) having the composition shown in Table 4 was prepared.
Solution (B) and solution (C) were prepared. 6 of solution (A)
Then, each of the two chambers made of polyethylene was filled with 00 ml and 300 ml of the solution (B) under nitrogen replacement, and a polyethylene mouth member having a polyethylene terephthalate small chamber was welded to the solution (A) side. And sealed. next,
The small chamber of the mouth member was filled with 4 ml of the solution (C) and sealed with a Teflon-coated rubber stopper. The autoclave was subjected to high-pressure steam sterilization according to an ordinary method to obtain an infusion for central venous administration of the present invention.

[0055]

[Table 4]

Test Example 2 The infusion solutions obtained in Examples 3 to 4 and Comparative Example 3 were subjected to a stability test in the same manner as in Test Example 1. Table 5 shows the results
The ratio to the blending amount is shown in percentage.

[0057]

[Table 5]

From the results shown in Table 5, the infusion of the present invention shows that
The content of each type of vitamin was within the allowable range even after being left for 4 months. On the other hand, in Comparative Example 3, since vitamin B ₁ is blended in the solution (B) and folic acid is blended in the solution (A), the contents of these are significantly reduced.

[Brief description of the drawings]

FIG. 1 is a diagram showing an example of a container for containing a solution (C).

FIG. 2 is a diagram showing a method of holding a container containing a solution (C) at one mouth of a two-chamber container containing a solution (A) and a solution (B) via a double-ended needle.

FIG. 3 is a view showing a method of communicating and mixing the solution by pressing the container of the solution (C) in the container shown in FIG. 2;

FIG. 4 is a view showing an example of a container for containing an infusion consisting of three liquids of the present invention.

FIG. 5 is a view showing an example of a container for containing an infusion consisting of three liquids of the present invention.

Continued on the front page (51) Int.Cl. ⁶ Identification code FI A61K 31/045 A61K 31/07 31/07 31/12 31/12 31/195 31/195 31/20 31/20 31/23 31/23 31/355 31/355 31/375 31/375 31/44 31/44 31/505 31/505 31/51 31/51 31/525 31/525 31/59 31/59 31/68 31/68 31 / 70 31/70 33/00 33/00 A61J 1/00 351A

Claims (10)

[Claims] 1. An infusion solution comprising a solution (A) containing a reducing sugar, a solution (B) containing an amino acid and a solution (C) containing a fat-soluble vitamin, wherein the solution (A) is a vitamin The solution (B) contains B ₁ , the solution (B) contains folic acid, the solution (C) contains vitamin C, and the vitamin B ₂ is mixed with the solution (B) or the solution (C), and the solution (A) Is pH
3.5-4.5, solution (B) and solution (C) have a pH of 5.5
An infusion for central venous administration, which is from 7.5 to 7.5. 2. The infusion for central venous administration according to claim 1, wherein the solution (A) further contains a pantothenic acid derivative, and vitamin B ₂ is incorporated in the solution (C). Wherein the solution (B) is, central venous administration infusion claim 1 or 2, wherein further containing vitamin B _12. 4. The solution according to claim 1, wherein the solution (A) further contains vitamin B ₆ , the solution (B) further contains a nicotinic acid derivative, and the solution (C) further contains biotin. The infusion for central venous administration according to any one of the above. 5. The infusion for central venous administration according to claim 1, wherein the solution (A) further contains vitamin B ₆ , vitamin B ₁₂ , a nicotinic acid derivative, a pantothenic acid derivative and biotin. 6. The infusion for central venous administration according to any one of claims 1 to 5, wherein the fat-soluble vitamin in the solution (C) is solubilized by a surfactant. 7. The infusion for central venous administration according to any one of claims 1 to 6, wherein the solution (C) is enclosed in a container whose inner wall is at least made of a material that does not substantially adsorb vitamin D. 8. A solution (C) wherein at least the inner wall is made of glass, polyethylene terephthalate, polyethylene naphthalate, polyacrylonitrile, cyclic polyolefin,
8. A container sealed in a container made of a material selected from polyamide, polycarbonate and polyfluoroethylene.
The infusion for central venous administration according to the above. 9. A container (A) and a solution (B) are respectively housed in each of two chambers separated by a communicable partition,
A container containing the solution (C) in one of the chambers
The infusion for central venous administration according to any one of claims 1 to 8, wherein the infusion is connected so as to be able to communicate when used. 10. The solution according to claim 1, wherein the electrolyte is blended with the solution (A) and / or the solution (B) and / or the solution (C).
10. The infusion for central venous administration according to any one of 9.